Related Videos
Video
Marlise Luskin, MD, MSCE discusses results of a phase 1 trial
Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial
Video
Dr. Marlise Luskin, a specialist in the Adult Leukemia Program at Dana-Farber Cancer Institute, explains an innovative trial that combines the BCL2 inhibitor, venetoclax with chemotherapy for older patients with ALL.
Video
Treatment for Adults with Acute Lymphoblastic Leukemia
Marlise Luskin, MD, MSCE, a leukemia specialist at Dana-Farber Cancer Institute describes treatment for adults with acute lymphoblastic leukemia (ALL). She explains treatment considerations for younger adults and older adults with ALL.